 |
|
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
Joo Hyun Oh, Dae Won Jun
Clin Mol Hepatol. 2024;30(2):168-170. Published online 2024 Mar 5 DOI: https://doi.org/10.3350/cmh.2024.0140
|
|
Citations to this article as recorded by
 Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020
Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu
BMC Gastroenterology.2025;[Epub] CrossRef Liver-related Events and Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease Varies With the Type of Cardiometabolic Risk Factor
Shekhar Swaroop, Sagnik Biswas, Shubham Mehta, Arnav Aggarwal, Umang Arora, Samagra Agarwal, Amitkumar Chavan, Baibaswata Nayak, Shalimar
Journal of Clinical and Experimental Hepatology.2025; 15(5): 102559. CrossRef Shared genetic architecture between metabolic dysfunction-associated steatotic liver disease and cardiometabolic traits comorbidities: a genome-wide pleiotropic and multi-omics study
Xuan-Yu Wang, Qiong Lyu, Yang-Yang Zhang, Yue Su, Hongjie Zhao, Hui-Hui Shen, Ying-Yu Xie
Metabolism and Target Organ Damage.2025;[Epub] CrossRef Association of advanced lung cancer inflammation index with all-cause and cardiovascular mortality in metabolic dysfunction associated steatotic liver disease
Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu
Scientific Reports.2025;[Epub] CrossRef Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease
Ying Wen, Yu Min, Yi Lei, Zhigong Wei, Sophia Eugenia Martínez-Vázquez
PLOS One.2025; 20(7): e0327772. CrossRef Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”
Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada
Clinical and Molecular Hepatology.2024; 30(2): 281. CrossRef Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2024; 30(4): 1033. CrossRef Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022
Jae Woo Park, Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang
The Korean Journal of Internal Medicine.2024; 39(6): 931. CrossRef
|